Reference List

References to papers published in scientific journals mentioned in this website are given below, where possible with the full paper if you would like to read more about it. In some cases, you will find that only a summary of the paper (the 'abstract') is available. This is because the publishers of the journals make a charge to download the full article.

All links open in a new browser window.

CCOHTA 1998. Otten N. Comparison of Drug treatments for Multiple Sclerosis. Ottawa: Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA) 1998 (www.ccohta.ca/publications/pdf/ms_tech_e.pdf)

Cochrane Gray 2004. Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis (Cochrane Review). The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd. ( www.update-software.com/abstracts/ab003208.htm)

Cochrane Munari 2004. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis (Cochrane Review). The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd. ( www.update-software.com/abstracts/ab004678.htm)

Cochrane Rice 2004. Rice G PA, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, Filippini G. Interferon in relapsing-remitting multiple sclerosis (Cochrane Review). The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd. (www.update-software.com/abstracts/ab002002.htm)

Edgar 2004. Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in
patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci. 2004
Feb;31(1):58-63. (www.cjns.org/31febtoc/lipoatrophy.html)

Francis 2003. Francis GS, Grumser Y, Alteri E, Micaleff A, O'Brien F, Alsop J, Stam Moraga
M, Kaplowitz N. Hepatic reactions during treatment of multiple sclerosis with
interferon-beta-1a: incidence and clinical significance. Drug Saf. 2003;26(11):815-27. (www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed& dopt=Abstract&list_uids=12908850)

Goodkin 1995. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, Van Dyke C. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995 Jan;37(1):30-40. (www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=7818255)

HSC 2002/004. Department of Health Health Service Circular. Cost effective provision of disease modifying therapies for people with Multiple Sclerosis (www.dh.gov.uk/assetRoot/04/01/22/14/04012214.pdf )

Kurtzke 1983. (EDRS) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Kurtzke JF. Neurology. 1983 Nov;33(11):1444-52. (www.neurology.org/cgi/content/abstract/33/11/1444)

Mancardi 2000. Mancardi GL, Murialdo A, Drago F, Brusati C, Croce R, Inglese M, Ratto S. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol. 2000 Mar;247(3):220-1.
(abstract not available online)

NICE 2002. National Institute for Clinical Excellence. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. Technology Appraisal Guidance - No.32. London 2002 (www.nice.org.uk/cat.asp?c=27588)

Palace 1997. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet. 1997 Jul 26;350(9073):261.
(abstract not available online)

Yudkin 1991. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, Mertin J, Milanese C. Overview of azathioprine treatment in multiple sclerosis. Lancet. 1991 Oct 26;338(8774):1051-5. (www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1681364)